Centene Corp (CNC) · Oct 26, 2026 · Earnings
Beat — Adjusted EPS $0.58 vs roughly $0.09–$0.10 consensus
Centene’s Q3 earnings beat expectations decisively, with adjusted EPS of $0.58 and a higher 2026 profit guidance floor despite shrinking membership.
Centene is in the middle of a profitability recovery: it is shrinking weaker Marketplace and Medicaid exposure while leaning harder on Medicare prescription drug plans, pricing actions, and cost cuts. Before the release, published Q3 expectations centered on roughly $0.09–$0.10 of adjusted EPS and about $47.1 billion of revenue, while the broader story already assumed improving margins but declining membership.
| Metric | Q3 2026 | Q3 2025 / consensus | Read-through |
|---|---|---|---|
| Adjusted diluted EPS | $0.58 | $0.50 / ~$0.09–$0.10 consensus | Clear beat (Non-GAAP EPS reconciliation) |
| Total revenues | $50.647B | $49.690B / ~$47.1B consensus | Above published expectation (Income Statement) |
| Premium and service revenue | $45.105B | $44.898B | Essentially flat, +0.5% (Segment results) |
| Health benefits ratio | 92.7% | 92.7% | Stable, but above the new full-year target range (Operating ratios) |
| Adjusted SG&A ratio | 6.5% | 7.0% | Meaningful efficiency improvement (Operating ratios) |
| 2026 adjusted EPS floor | >$5.20 | Prior floor >$4.80 | Raised (Full-year guidance) |
| 2026 HBR guidance | 90.4%–91.1% | Prior range 90.5%–91.3% | Slightly lowered (Full-year guidance) |
The earnings beat is much larger than the headline business growth. Adjusted EPS of $0.58 was far above the roughly $0.09–$0.10 published consensus, while total revenue of $50.647 billion also exceeded the roughly $47.1 billion expectation. The underlying revenue mix was less impressive: Medicaid revenue rose 4% and Medicare revenue rose 20%, but Commercial revenue fell 21%, leaving premium and service revenue up only 0.5%. (Segment results) The filing says, “For the third quarter of 2026, premium and service revenues increased 0.5% to $45.1 billion from $44.9 billion in the comparable period of 2025.”
The margin recovery is the real substance behind the beat. The health benefits ratio held at 92.7%, while adjusted SG&A fell to 6.5% from 7.0%, helped by lower Marketplace membership, operating leverage, and the faster-growing PDP business. That means Centene generated substantially more earnings without needing broad top-line growth. (Operating ratios) The filing says, “The decrease in the adjusted SG&A expense ratio was driven by strong cost management, leveraging of expenses over higher revenues and reduced Marketplace membership.”
Management raised the profit outlook, but it also lowered the medical-cost guardrail. The adjusted EPS floor moved above $5.20 from the prior $4.80 floor, and the GAAP floor rose above $3.46 from $3.11. At the same time, full-year HBR guidance was reduced to 90.4%–91.1% from the prior 90.5%–91.3% range, indicating that the earnings upgrade is being driven more by operating efficiency, mix, and other items than by a cleaner medical-cost outlook. (Full-year guidance) The filing says, “The Company is updating its 2026 GAAP diluted EPS guidance floor to greater than $3.46 and its 2026 adjusted diluted EPS guidance floor to greater than $5.20.”
The recovery still comes with a shrinking membership base. Total at-risk membership declined to 25.7 million from 28.0 million a year earlier, driven mainly by Marketplace and Medicaid losses, even as PDP membership grew. That mix shift is helping profitability now, but it makes the recovery dependent on retaining margin while the company serves fewer members. (Membership)
Capital allocation reinforces the recovery rather than changing the story. Centene repurchased $558 million of senior notes during the quarter, then retired the remaining $569 million of notes due in 2027 after expanding the repurchase authorization. Debt fell to $15.5 billion, with no revolver borrowings at quarter-end. (Liquidity and debt) The filing says, “During the third quarter of 2026, the Company repurchased $558 million of the Company's par value senior notes due 2027 and 2028.”
Bottom line: This is a genuine upside reset to Centene’s recovery story: Q3 earnings beat by a wide margin and the full-year profit floor rose materially. The caveat is that the improvement is coming alongside continued membership contraction and a slightly less favorable medical-cost outlook, so the key question shifts to whether the leaner, more Medicare/PDP-heavy model can sustain these margins into 2027.
2027 outlook at Q4 results
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!